[go: up one dir, main page]

BR0008365A - 2-amino-6-anilino-purinas e o seu uso comomedicamento - Google Patents

2-amino-6-anilino-purinas e o seu uso comomedicamento

Info

Publication number
BR0008365A
BR0008365A BR0008365-8A BR0008365A BR0008365A BR 0008365 A BR0008365 A BR 0008365A BR 0008365 A BR0008365 A BR 0008365A BR 0008365 A BR0008365 A BR 0008365A
Authority
BR
Brazil
Prior art keywords
anilino
amino
purines
medicine
diseases
Prior art date
Application number
BR0008365-8A
Other languages
English (en)
Inventor
Patricia Imbach
Hans-George Capraro
Juerg Zimmermann
Giorgio Caravatti
Pascal Furet
Wolfang Karl-Diether Brill
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0008365A publication Critical patent/BR0008365A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: "2-AMINO-6-ANILINO-PURINAS E O SEUUSO COMO MEDICAMENTO". Na qual os símbolos, que são deacordo com a definição da reivindicação 1, são descritos. Estescompostos inibem a quinase de P34 ^ cdc2^/CiClina B~ cdc13~ equinase da tirosina da proteína pp60^ c-src^ e podem serutilizados para o tratamento de doenças hiperproliferativas, como,por exemplo, doenças de tumor e doenças que respondem àinibição da atividade da quinase tirosina da proteína pp60^ c-src^,em particular, osteporose.
BR0008365-8A 1999-02-18 2000-02-16 2-amino-6-anilino-purinas e o seu uso comomedicamento BR0008365A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903762.4A GB9903762D0 (en) 1999-02-18 1999-02-18 Organic compounds
PCT/EP2000/001271 WO2000049018A1 (en) 1999-02-18 2000-02-16 2-amino-6-anilino-purines and their use as medicaments

Publications (1)

Publication Number Publication Date
BR0008365A true BR0008365A (pt) 2001-11-13

Family

ID=10848053

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008365-8A BR0008365A (pt) 1999-02-18 2000-02-16 2-amino-6-anilino-purinas e o seu uso comomedicamento

Country Status (13)

Country Link
US (1) US6767906B2 (pt)
EP (1) EP1153024B1 (pt)
JP (1) JP2002537300A (pt)
CN (1) CN1183133C (pt)
AT (1) ATE265456T1 (pt)
AU (1) AU3804500A (pt)
BR (1) BR0008365A (pt)
CA (1) CA2360353A1 (pt)
DE (1) DE60010234T2 (pt)
ES (1) ES2219326T3 (pt)
GB (1) GB9903762D0 (pt)
PT (1) PT1153024E (pt)
WO (1) WO2000049018A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0874846B1 (en) * 1995-11-01 2003-04-02 Novartis AG Purine derivatives and processes for their preparation
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US7115589B2 (en) * 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0127615D0 (en) 2001-07-09 2002-01-09 Aventis Pharm Prod Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
AU2002320330B2 (en) * 2001-07-09 2007-06-14 Aventis Pharmaceuticals Inc. Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
JP4664205B2 (ja) * 2002-10-15 2011-04-06 アイアールエム エルエルシー 骨形成を誘導する組成物および方法
JP2006514646A (ja) * 2002-12-13 2006-05-11 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのシクロヘキシル化合物類
US7160834B2 (en) * 2003-03-18 2007-01-09 Exxonmobil Chemical Patents Inc. Soluble group-10 α-diimine catalyst precursors, catalysts and methods for dimerizing and oligomerizing olefins
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
EP1682150B1 (en) * 2003-11-10 2012-12-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
JP5321061B2 (ja) * 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
CA2623374A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101148449B (zh) * 2006-09-20 2010-08-11 浙江医药股份有限公司新昌制药厂 2-(6-喹啉氨基)-6-环丙氨基-9h-嘌呤成盐的方法
US9408848B2 (en) * 2008-08-15 2016-08-09 Georgetown University Fluorescent CDK inhibitors for treatment of cancer
AU2009314631B2 (en) 2008-11-12 2014-07-31 Takeda Pharmaceutical Company Limited Pyrazinopyrazines and derivatives as kinase inhibitors
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2012115575A1 (en) * 2011-02-21 2012-08-30 Biomatcell Ab Derivatives for inducing osteogenic differentiation
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
WO2014123882A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. 2,6,7 substituted purines as hdm2 inhibitors
CN116492347A (zh) * 2013-09-18 2023-07-28 华安医学股份有限公司 一种活化ampk的化合物及其用途
WO2015039612A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1246645A1 (zh) * 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
EP3518925A4 (en) * 2016-09-30 2020-04-15 SRI International DUAL CLK / CDK1 INHIBITORS FOR CANCER TREATMENT
AU2017369753A1 (en) * 2016-12-01 2019-07-18 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN114945572B (zh) * 2019-03-26 2025-01-28 周美吟 用于治疗镰状血球贫血症及β-地中海型贫血的HBF药理诱导化合物
AU2023393410A1 (en) 2022-12-16 2025-07-31 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE212535C (pt)
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5565566A (en) 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5066655A (en) 1987-04-24 1991-11-19 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
CA1340361C (en) 1987-04-24 1999-02-02 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
EP0457773A4 (en) 1989-01-31 1993-03-10 Whitby Research Incorporated N?6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
EP0874846B1 (en) * 1995-11-01 2003-04-02 Novartis AG Purine derivatives and processes for their preparation
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6255485B1 (en) * 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines

Also Published As

Publication number Publication date
PT1153024E (pt) 2004-08-31
JP2002537300A (ja) 2002-11-05
GB9903762D0 (en) 1999-04-14
EP1153024B1 (en) 2004-04-28
WO2000049018A1 (en) 2000-08-24
ES2219326T3 (es) 2004-12-01
CN1183133C (zh) 2005-01-05
US6767906B2 (en) 2004-07-27
HK1042479A1 (en) 2002-08-16
EP1153024A1 (en) 2001-11-14
ATE265456T1 (de) 2004-05-15
DE60010234T2 (de) 2005-04-14
US20020016329A1 (en) 2002-02-07
DE60010234D1 (de) 2004-06-03
CA2360353A1 (en) 2000-08-24
CN1340054A (zh) 2002-03-13
AU3804500A (en) 2000-09-04

Similar Documents

Publication Publication Date Title
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
ATE324877T1 (de) Behandlung von metastatischer krankheit
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
DK0888353T3 (da) N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0016817A (pt) Combinações de um inibidor de quinase do receptor de tirosina com um composto orgânico capaz de se ligar à alfa1-glicoproteìna ácida
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
BG104813A (bg) Заместени индолинони с инхибиращ ефект върху кинази и комплекси циклин/cdk
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
HUP0204141A2 (hu) Pirido[2,3-d]pirimidin-2,7-diamin típusú kináz-inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BG104938A (bg) Заместени индолинони, тяхното получаване и тяхното приложение като лекарствени средства
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ATRAVES DA PETICAO NO 7920 DE 17/02/2003, O REQUERENTE SOLICITOU O EXAME DO PRESENTE PEDIDO E EFETUOU A RETRIBUICAO EQUIVALENTE A 19 REIVINDICACOES. NO ENTANTO, NO QUADRO REIVINDICATORIO APRESENTANDO CONSTAM 21 REIVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO EQUIVALENTE A 02 ( DUAS ) REIVINDICACOES EXCEDENTE.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13, 24, 25 E 10(VIII) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.